MedTrace Logo

Lung Allograft Rejection Gene Expression Observational (LARGO) Study

NCT00751309 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2044

Last updated 2008-12-18

No results posted yet for this study

Summary

The objective of the LARGO Study protocol is to collect peripheral blood samples, select associated lung biopsy pathology slides, and clinical data from lung transplant recipients to perform molecular analyses in association with the study endpoints. The primary objective is to use gene expression profiling of peripheral blood mononuclear cells to differentiate between the absence and presence of acute cellular rejection. The secondary objectives are to use other genomic and proteomic technologies to analyze RNA and protein in blood samples in relation to related clinical conditions. The overall goal is to apply novel molecular insights in the development of non-invasive molecular diagnostic tests for lung transplantation.

Conditions

Interventions

OTHER

Non-interventional

Post-transplantation observational study

Sponsors & Collaborators

  • XDx

    lead INDUSTRY

Principal Investigators

  • Kenneth C. Fang, MD · XDx, Inc.

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States
  • Austria
  • Canada
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00751309 on ClinicalTrials.gov